From: FiercePharma By: Noah Higgins-Dunn   The analysts based the belief on the latest survey results from Spherix Global Insights,...

From: Daily Mail By: Mansur Shaheen     A survey of neurologists by Spherix Global Insights found that neurologists only...

From: FiercePharma By: Beth Snyder Bulik While almost 90% of neurologists are moderately or highly aware of Aduhelm, only 3%...

From: Multiple Sclerosis News Today By: Marta Figueiredo, PhD   Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently...

Subgroup disparities such as sex and race are more significant among patients with migraine, according to the results of a...

Migraine diagnoses, treatment and management varied by race and sex among a sample of patients that was “evenly distributed” across...

From: Multiple Sclerosis News Today By: Marta Figueiredo, PhD Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Ocrevus (ocrelizumab) are losing ground to more recent therapies among...

From: Multiple Sclerosis News Today By: Marta Figueiredo     Genentech’s Ocrevus (ocrelizumab) continues to be the most prescribed treatment...

From: Multiple Sclerosis News Today By: Marta Figueiredo Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or...

From: MDedge Neurology By: Bruce Jancin The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in...

From: MigraineAgain By: Lori Smith   At this time, there is no safety reason for not allowing people to try...